The human papillomavirus type 16 encodes two principal oncoproteins, E6 and E7. The E7 protein has been shown to deregulate the cell cycle through interactions with a variety of proteins involved in cell cycle control and transcriptional regulation. These activities result in E7 being able to cooperate with activated oncogenes in the transformation of primary rodent cells, and with the viral E6 protein during human keratinocyte immortalization. Although a large number of activities have been ascribed to the E7 protein, little is known about its regulation during the cell cycle. We have performed a series of studies to investigate potential changes in E7 phosphorylation during the cell cycle and we show that E7 is indeed differentially phosphorylated. Casein kinase II is the principal kinase during the early part of the cell cycle, but this activity decreases rapidly as cells progress toward S phase. In addition, E7 is transiently phosphorylated at Ser71 in S phase by another, as yet unknown, kinase. These results demonstrate differential regulation of the E7 protein during the cell cycle that most likely represents a means of providing specificity to E7's activities.
INTRODUCTION
Human papillomaviruses (HPVs) are the causative agents of a number of human cancers, in particular cervical cancer, in which HPV types 16 and 18 are predominately found (zur Hausen and Schneider, 1987) . These viruses encode two major oncoproteins, E6 and E7. Both interfere with key elements in the cell cycle control machinery and, as a result, induce cell cycle progression in normally quiescent cells. While a major role of E6 appears to be to overcome host-induced apoptosis (Pan and Griep, 1995; Thomas and Banks, 1998) , the E7 protein is largely responsible for induction of the host DNA replication machinery (Bandara et al., 1991; Phelps et al., 1991) . HPV-16 E7 has been reported to interact with a large number of cellular target proteins and displays a large number of different phenotypic effects (Dyson et al., 1989; Davies et al., 1993; Tommasino et al., 1993; Antinore et al., 1996; Massimi et al., 1996; Zwerschke et al., 1999) ; however, a number of major questions remain. It is presently unclear what provides specificity to these different E7 interactions, since it is unlikely that all could be carried out simultaneously. In addition, there is no information as to whether E7 itself might also be regulated during the cell cycle.
Phosphorylation represents a common means by which proteins can be differentially regulated. Previous studies have shown that E7 is phosphorylated by casein kinase II (CKII) and that mutations which block this activity reduce E7's transforming ability (Barbosa et al., 1990; Storey et al., 1990; Firzlaff et al., 1991) , suggesting that phosphorylation by CKII is a significant factor in regulating the function of E7. Another report also suggested that E7 could be phosphorylated at additional sites within the protein (Storey et al., 1990) , but no further studies on this have been reported. A number of studies have also shown that CKII activity varies during the cell cycle (Russo et al., 1992; Pepperkok et al., 1994; Lorenz et al., 1999) . We were therefore interested in investigating the phosphorylation status of the HPV-16 E7 protein as cells enter the cell cycle, since this is the point at which E7 would appear to exert most of its activities. We show that E7 is highly phosphorylated by CKII during the G1 phase of the cell cycle, but this rapidly decreases as cells enter S phase. However, at this time E7 becomes phosphorylated on serine 71 by another, as yet unknown, kinase. These results demonstrate that E7 is indeed differentially phosphorylated during the cell cycle.
RESULTS AND DISCUSSION
To investigate the phosphorylation of E7 during the cell cycle we first performed an in vivo labeling experiment and immunoprecipitation analysis at different points during the cell cycle. Transformed baby rat kidney epithelial cells expressing HPV-16 E7 and EJ-ras were growth-arrested in low serum for 48 h and then induced to reenter the cell cycle by addition of 10% fetal calf serum. At the same time the cells were labeled for 1 h with [
32 P]-orthophosphate at different times post addition of serum. Cell extracts were then made and the radiolabeled E7 was detected by immunoprecipitation. The results are shown in Fig. 1 . The upper part of the figure shows the level of bromodeoxyuridine (BUDR) incorporation. This shows first that the cells are indeed growth arrested and, second that the cells are in maximal S phase approximately 6 h post addition of serum. As can be seen in Fig. 1B there are two different patterns of E7 phosphorylation. At time zero HPV-16 E7 is heavily phosphorylated but as the cells enter the cycle this rapidly decreases. However, at time points close to maximal S phase there is again an increase in the levels of E7 phosphorylation. The lower panel shows the parallel Western blot which demonstrates that there are constant levels of E7 protein during the course of the experiment. These results show that E7 is differentially phosphorylated during the cell cycle.
Since HPV-16 E7 has previously been shown to be phosphorylated by CKII (Barbosa et al., 1990) , we next investigated whether these changes in the phosphorylation status of E7 were due to changes in CKII activity. To do this, wild-type E7 and an E7 mutant (31Ser32Ser/31Arg32Pro) that is defective for CKII phosphorylation (Barbosa et al., 1990) were produced as GST fusion proteins and purified. Extracts were made form the BRK cells that had been growth arrested and serum induced, as described above, and in vitro kinase assays were then performed on the two GST fusion proteins. The results obtained are shown in Fig.  2 and it is clear that the wild-type E7 protein is phosphorylated in a manner very similar to that seen in vivo. The protein is heavily phosphorylated by extracts from the growth-arrested cells, and this kinase activity subsequently decreases as the cells enter the cycle. However, a marked increase in E7 phosphorylation is obtained with extracts from cells approaching maximal S phase. Strikingly, the CKII defective mutant of E7 is not phosphorylated with extracts from the growth-arrested cells, but once the cells reach maximal S phase a very similar pattern of phosphorylation is seen to that obtained with the wild-type protein.
These results demonstrate that CKII specifically phosphorylates E7 early in the cell cycle, but as cells enter S phase this activity dramatically decreases. In addition, E7 is heavily phosphorylated later in S phase by another, as yet unidentified, kinase.
In order to verify that E7 defective for CKII phosphorylation is indeed phosphorylated in vivo, immunoprecipitation analysis was performed on BRK cells transformed with either wild-type E7 or two mutants of E7 defective for CKII phosphorylation, p31/32ArgPro and p31/32As-pAsp. Cells were radiolabeled in the presence of [ 32 P]orthophosphate and after 1 h cells were harvested and immunoprecipitations were performed as described previously (Banks and Crawford, 1988) . The results obtained are shown in Fig. 3A . As can be seen, both the wild-type and the mutant E7 proteins are phosphorylated, although p31/32ArgPro is much weaker than the wild-type or the p31/32AspAsp mutant. Western blot analysis of the E7 protein in the different cell lines is shown in Fig. 3B and it is clear that the p31/32AspAsp mutant is more highly expressed than either wild-type E7 or the p31/32ArgPro mutant. It is clear from this analysis that p31/32AspAsp is phosphorylated, confirming the specificity of the in vitro kinase assays, and demonstrates that E7 is indeed phosphorylated at residues other than at the CKII recognition site. Since the above assays were performed in BRK cells transformed with E7 and EJ-ras, we next investigated the pattern of E7 phosphorylation in keratinocytes lacking HPV DNA sequences. To do this, in vitro kinase assays were performed on GST-E7 as described for Fig. 2 , using extracts derived from HaCat cells at different phases of the cell cycle. The results obtained are shown in Fig. 4A and again demonstrate high levels of E7 phosphorylation in growth-arrested cells, followed by a decrease as cells are stimulated to enter the cell cycle. This is then followed by a marked increase in phosphorylation as the cells enter S phase. Figure 4B shows the cell cycle analysis confirming the entry into S phase 4 h post addition of serum. These results demonstrate that E7 is also differentially phosphorylated using extracts of keratinocytes at different phases of the cell cycle.
Previous studies had indicated a weak phosphorylation of E7 within the carboxy terminus of the protein at Ser71 (Storey et al., 1990) . In order to investigate the role of this potential phosphorylation site in the differential phosphorylation of E7, we expressed the Ser71/Gly71 E7 mutant (Storey et al., 1990 ) as a GST fusion protein and then repeated the in vitro phosphorylation analysis. The results obtained are shown in Fig. 5 . As can be seen, the wild-type E7 is again phosphorylated in a manner similar to that seen in Fig. 2 . Interestingly, the Ser71 mutant is phosphorylated by extracts from the growth-arrested cells, which is consistent with this phosphorylation being performed by CKII. However, no phosphorylation of the Ser71 mutant is seen later in the cell cycle, suggesting that phosphorylation of E7 during S phase occurs at Ser71.
Previous studies showing that HPV-16 E7 was phosphorylated gave no information about how this might change during the cell cycle (Barbosa et al., 1990; Storey et al., 1990; Massimi et al., 1996) . However, E7 phosphorylation is an important modification since mutants of E7 which are defective for CKII phosphorylation are also reduced in their ability to transform cells (Barbosa et al., 1990; Storey et al., 1990; Firzlaff et al., 1991) . In this study we have shown conclusively that CKII activity on E7 changes dramatically as cells progress through the cell cycle. Since the cells growth arrested by serum starvation enter S phase quite rapidly upon serum addition, the serum-starved BRK cells are most likely arrested in mid to late G1. Clearly, during this phase of the cell cycle there is very heavy CKII phosphorylation of E7. This is consistent with the notion that CKII phosphorylation affects E7's ability to induce cell transformation and also contributes to its ability to induce DNA synthesis (Banks et al., 1990a) , the latter activity of E7 being at its peak during mid to late G1. However, once cells enter S phase the CKII phosphorylation of E7 decreases dramatically and this is consistent with the role of E7 changing at this point in the cycle. Interestingly, as cells reach maximal S phase E7 is phosphorylated by another unknown kinase at Ser71. At present it is not clear what effect this phosphorylation event has upon E7 function, since previous studies had indicated that this mutant E7 could transform BRK cells with wild-type efficiency (Storey et al., 1990) . It should also be borne in mind that these assays are based on cells that enter the cell cycle from a serum-arrested state and it will now be of interest to analyze E7 phosphorylation status in normal cycling cells.
HPV-16 E7 is a multifunctional protein with many different cellular targets and activities. A key question concerning the activities of such small and low-abundance DNA tumor virus proteins is how they can possibly perform so many apparently divergent tasks. The data presented here begin to provide some of the answers to this question. Clearly differential phosphorylation of E7 is likely to alter its function during different phases of the cell cycle. This implies that E7 has defined activities at specific points within the cell cycle and that phosphorylation of the viral protein gives specificity to these functions. Studies are now in progress to identify the Ser71 kinase and to assess the interactions of E7 with its different target proteins during the cell cycle.
MATERIALS AND METHODS

Cells
Transformed BRK cells expressing HPV-16 E7 and EJras were obtained as described previously (Massimi et al., 1997) . BRK cells and HaCat cells were grown in DMEM supplemented with 10% fetal calf serum.
In vivo labeling and immunoprecipitation
BRK cells were placed in 0.2% fetal calf serum for 48 h and then placed in phosphate-free medium for a further 2 h. After this time 1 mCi [ 32 P]orthophosphate was added to the time zero cells for 1 h. The remaining cells were induced with 10% fetal calf serum and labeled with 1 mCi [ 32 P]orthophosphate for 1 h at different times after serum addition. Cells were harvested at 2-h intervals, extracted with E1a buffer as described previously (Banks and Crawford, 1988) , and immunoprecipitated with a rabbit polyclonal anti-E7 antibody. Immunoprecipitates were run on SDS-PAGE and analyzed by autoradiography. 
Cell cycle analysis
Cells were plated on coverslips and placed in 0.2% serum for 48 h. Medium was then added containing 10% fetal calf serum, and 20 mM BUDR (Sigma) was added for periods of 1 h at different time points post addition of serum. Immunofluorescence was then performed using anti-BUDR antibody (Sigma) and cells were counterstained with Hoechst solution. The percentage of BUDR-positive cells versus the number of total cells was then calculated for each time point. Alternatively, cells were harvested at different times post addition of serum and DNA content was assessed by propidium iodide staining and FACS analysis as described previously (Banks et al., 1990b) .
In vitro kinase assays
BRK cells were placed in 0.2% fetal calf serum for 48 h, after which time 10% fetal calf serum was added back to the cells and cells were extracted in lysis buffer (250 mM NaCl, 0.15% NP-40, 50 mM HEPES pH 7, 1% aprotinin, 100 M TLCK, 200 M TPCK, 50 mM NaF, 4 mM Na 3 VO 4 , 100 mM K 2 HPO 4 ) at different time points post addition of serum. Equal amounts of purified GST fusion proteins were then incubated with the   FIG. 4 . In vitro phosphorylation of the GST.16E7 fusion protein with HaCat cell extracts. (A) HaCat cells were growth arrested and cell extracts were obtained at different times post addition of serum. The purified E7 fusion protein was then subjected to in vitro kinase assays with the cell extracts in the presence of radiolabeled ␥ATP. Following extensive washing the radiolabeled proteins were analysed by SDS-PAGE and autoradiography. (B) FACS analysis of growth-arrested HaCat cells (time 0) and at subsequent 2-h intervals post addition of serum. As can be seen, maximal S phase is obtained between 4 and 6 h post addition of serum. This is followed by entry into G2M and G1 by 8 h.
cell extracts for 20 min at 30°C in phosphorylation buffer (20 mM HEPES, pH 7.5, 20 mM MgCl 2 , 0.3 M aprotinin, 1 M/Pepstatin) containing 56 nM [ 32 P]ATP (Amersham) and 10 M ATP. After being extensively washed, the phosphorylated proteins were monitored by SDS-PAGE and autoradiography. The level of phosphorylation was quantitated using a Packard Instant Phosphor Imager.
Western blotting
Extracts were prepared from serum-stimulated BRK cells at different time points post addition of serum, as described previously (Banks and Crawford, 1988 ). Proteins were then run on SDS-PAGE and transferred to nitrocellulose and E7 was detected using a rabbit anti-E7 polyclonal antibody and ECL detection according to the manufacturer's instructions (Amersham).
GST fusion proteins
These were induced and purified as described previously (Massimi et al., 1996) .
